Podcast
Brought to you by
Season 5 • Episode 23

Radical Clarity in Drug Pricing: How Rescription Uses the 340B Program and Patented Tech to Lower Costs

Scott Martin, Founder & CEO at Rescription

Episode Highlights
Scott explains how Rescription's model differs from traditional PBMs
Timestamp: 01:16
Clarifying misconceptions about the 340B program
Timestamp: 03:09
Updates on partnerships with Bergen New Bridge and Baton Rouge General
Timestamp: 05:14
How Rescription addresses pharmaceutical manufacturer pushback
Timestamp: 07:25
Details on Rescription's patent-pending adjudication technology
Timestamp: 09:24
Future expansion plans and new service offerings
Timestamp: 11:15

About this episode

In this episode of Product in Healthtech, we reconnect with Scott Martin, founder and CEO of Rescription, to discover how his company has evolved since our previous conversation.

Subscribe
Follow Name Scott Martin
LinkedIn

About Rescription

Rescription, a healthcare startup led by Scott Martin, is disrupting prescription drug affordability through their innovative approach to the 340B federal program. Since launching in 2023, they've achieved 30% savings for health systems while providing zero-dollar copays to patients, and are now expanding to 14 states with their patent-pending adjudication technology.

Your Strategic Product Development Partner | © 2025 VYNYL LLC